journal
MENU ▼
Read by QxMD icon Read
search

Expert Opinion on Therapeutic Targets

journal
https://www.readbyqxmd.com/read/29022407/the-potential-of-kdm3a-as-a-therapeutic-target-in-ewing-sarcoma-and-other-cancers
#1
Paul Jedlicka
No abstract text is available yet for this article.
October 12, 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28994330/molecular-mechanisms-and-theranostic-potential-of-mirnas-in-drug-resistance-of-gastric-cancer
#2
Wanli Yang, Jiaojiao Ma, Wei Zhou, Bo Cao, Xin Zhou, Zhiping Yang, Hongwei Zhang, Qingchuan Zhao, Daiming Fan, Liu Hong
Systemic chemotherapy is a curative approach to inhibit gastric cancer cells proliferation. Despite the great progress in anti-cancer treatment achieved during the last decades, drug resistance and treatment refractoriness still extensively persists. Recently, accumulating studies have highlighted the role of miRNAs in drug resistance of gastric cancers by modulating some drug resistance-related proteins and genes expression. Pre-clinical reports indicate that miRNAs might serve as ideal biomarkers and potential targets, thus holding great promise for developing targeted therapy and personalized treatment for the patients with gastric cancer...
October 10, 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28971703/stxbp1-as-a-therapeutic-target-for-epileptic-encephalopathy
#3
Hannah Stamberger, Sarah Weckhuysen, Peter De Jonghe
STXBP1 is an essential protein for presynaptic vesicle release. Mutations in STXBP1 have been associated with a series of (epileptic) neurodevelopmental disorders collectively referred to as STXBP1-encephalopathy (STXBP1-E). In this review we hypothesize about the potential of STXBP1 as a therapeutic target in the field of epileptic encephalopathies. Areas covered: A state of the art overview on current understanding of the pathophysiologic mechanism underlying STXBP1-E is presented. Possibilities of different treatment modalities are discussed including unbiased compound screening, specific protein-protein interaction inhibition and gene therapy, consisting either of gene suppletion or upregulation of gene expression...
October 5, 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28960088/adam10-as-a-therapeutic-target-for-brain-diseases-from-developmental-disorders-to-alzheimer-s-disease
#4
Elena Marcello, Barbara Borroni, Silvia Pelucchi, Fabrizio Gardoni, Monica Di Luca
Introduction In the central nervous system a disintegrin and metalloproteinase 10 (ADAM10) controls several functions such as neurodevelopment, synaptic plasticity and dendritic spine morphology thanks to its activity towards a high number of substrates, including the synaptic cell adhesion molecules as the Amyloid Precursor Protein, N-cadherin, Notch and Ephrins. In particular, ADAM10 plays a key role in the modulation of the molecular mechanisms responsible for dendritic spine formation, maturation and stabilization and in the regulation of the molecular organization of the glutamatergic synapse...
September 29, 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28956957/the-potential-of-targeting-sin3b-and-its-associated-complexes-for-cancer-therapy
#5
David J Cantor, Gregory David
Sin3B serves as a scaffold for chromatin-modifying complexes that repress gene transcription to regulate distinct biological processes. Sin3B-containing complexes are critical for cell cycle withdrawal, and abrogation of Sin3B-dependent cell cycle exit impacts tumor progression. Areas covered: In this review, we discuss the biochemical characteristics of Sin3B-containing complexes and explore how these complexes regulate gene transcription. We focus on how Sin3B-containing complexes, through the association of the Rb family of proteins, repress the expression of E2F target genes during quiescence, differentiation, and senescence...
September 28, 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28952395/open-angle-glaucoma-therapeutically-targeting-the-extracellular-matrix-of-the-conventional-outflow-pathway
#6
Jeffrey O'Callaghan, Paul S Cassidy, Pete Humphries
Ocular hypertension in open-angle glaucoma is caused by a reduced rate of removal of aqueous humour (AH) from the eye, with the majority of AH draining from the anterior chamber through the conventional outflow pathway, comprising the trabecular meshwork (TM) and Schlemm's Canal. Resistance to outflow is generated, in part, by the extracellular matrix (ECM) of the outflow tissues. Current pressure-lowering topical medications largely suppress AH production, or enhance its clearance through the unconventional pathway...
September 27, 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28922023/fatty-acid-synthase-fasn-as-a-therapeutic-target-in-breast-cancer
#7
Javier A Menendez, Ruth Lupu
Ten years ago, we put forward the metabolo-oncogenic nature of fatty acid synthase (FASN) in breast cancer. Since the conception of this hypothesis, which provided a model to explain how FASN is intertwined with various signaling networks to cell-autonomously regulate breast cancer initiation and progression, FASN has received considerable attention as a therapeutic target. However, despite the ever-growing evidence demonstrating the involvement of FASN as part of the cancer-associated metabolic reprogramming, translation of the basic science-discovery aspects of FASN blockade to the clinical arena remains a challenge...
September 18, 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28847189/does-herv-k-represent-a-potential-therapeutic-target-for-prostate-cancer
#8
Wolfgang A Schulz
No abstract text is available yet for this article.
August 30, 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28849678/corrigendum
#9
(no author information available yet)
No abstract text is available yet for this article.
August 29, 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28836878/role-of-shared-epitope-and-other-citrullination-sites-in-rheumatoid-arthritis-and-in-melanoma
#10
Daniela D'Arcangelo, Antonio Facchiano, Angelo M Facchiano
No abstract text is available yet for this article.
August 24, 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28829212/targeting-methionine-cycle-as-a-potential-therapeutic-strategy-for-immune-disorders
#11
Heng Li, Huimin Lu, Wei Tang, Jianping Zuo
Methionine cycle plays an essential role in regulating many cellular events, especially transmethylation reactions, incorporating the methyl donor S-adenosylmethionine (SAM). The transmethylations and substances involved in the cycle have shown complicated effects and mechanisms on immunocytes developments and activations, and exert crucial impacts on the pathological processes in immune disorders. Areas covered: Methionine cycle has been considered as an effective means of drug developments. This review discussed the role of methionine cycle in immune responses and summarized the potential therapeutic strategies based on the cycle, including SAM analogs, methyltransferase inhibitors, S-adenosylhomocysteine hydrolase (SAHH) inhibitors, adenosine receptors specific agonists or antagonists and homocysteine (Hcy)-lowering reagents, in treating human immunodeficiency virus (HIV) infections, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), systemic sclerosis (SSc) and other immune disorders...
August 22, 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28831824/vegf-as-a-potential-target-in-lung-cancer
#12
REVIEW
Daniela Frezzetti, Marianna Gallo, Monica R Maiello, Amelia D'Alessio, Claudia Esposito, Nicoletta Chicchinelli, Nicola Normanno, Antonella De Luca
Introduction The vascular endothelial growth factor A (VEGF) is the main mediator of angiogenesis. In addition, VEGF contributes to cancer growth and metastasis directly targeting tumor cells. VEGF overexpression and/or high VEGF serum levels have been reported in lung cancer. Areas covered We searched Pubmed for relevant preclinical studies with the terms 'lung cancer' 'VEGF' and 'in vivo'. We also searched the Clinicaltrials.gov database, the FDA and the EMA websites for the most recent updates on clinical development of anti-VEGF agents...
October 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28829211/fibroblast-activation-protein-%C3%AE-in-fibrogenic-disorders-and-cancer-more-than-a-prolyl-specific-peptidase
#13
REVIEW
Lucienne Juillerat-Jeanneret, Petra Tafelmeyer, Dela Golshayan
Fibroblast activation protein-α (FAP-α) belongs to the family of prolyl-specific serine proteases. FAP-α displays both exopeptidase and endopeptidase/gelatinase/collagenase activities. FAP-α protein and/or activity have been associated with fibrosis, inflammation and cancer, but the protein is undetectable in most normal tissues. FAP-α is selectively expressed at sites of tissue remodeling and repair and enhances tumor progression, suggesting that this protease may be a therapeutic target to treat human disorders associated with fibrotic dysregulation...
October 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28829206/new-perspectives-on-ckd-induced-dyslipidemia
#14
REVIEW
Marcelino Bermúdez-López, David Arroyo, Àngels Betriu, Luis Masana, Elvira Fernández, Jose M Valdivielso
Chronic kidney disease (CKD) is a world-wide health concern associated with a significantly higher cardiovascular morbidity and mortality. One of the principal cardiovascular risk factors is the lipid profile. CKD patients have a more frequent and progressive atheromatous disease that cannot be explained by the classical lipid parameters used in the daily clinical practice. Areas covered: The current review summarizes prevailing knowledge on the role of lipids in atheromathosis in CKD patients, including an overview of lipoprotein metabolism highlighting the CKD-induced alterations...
October 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28825343/agrin-lrp4-musk-signaling-as-a-therapeutic-target-for-myasthenia-gravis-and-other-neuromuscular-disorders
#15
REVIEW
Kinji Ohno, Bisei Ohkawara, Mikako Ito
Signal transduction at the neuromuscular junction (NMJ) is compromised in a diverse array of diseases including myasthenia gravis, Lambert-Eaton myasthenic syndrome, Isaacs' syndrome, congenital myasthenic syndromes, Fukuyama-type congenital muscular dystrophy, amyotrophic lateral sclerosis, and sarcopenia. Except for sarcopenia, all are orphan diseases. In addition, the NMJ signal transduction is impaired by tetanus, botulinum, curare, α-bungarotoxin, conotoxins, organophosphate, sarin, VX, and soman to name a few...
October 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28796572/endoglin-and-alk1-as-therapeutic-targets-for-hereditary-hemorrhagic-telangiectasia
#16
REVIEW
Lidia Ruiz-Llorente, Eunate Gallardo-Vara, Elisa Rossi, David M Smadja, Luisa M Botella, Carmelo Bernabeu
Hereditary Haemorrhagic Telangiectasia (HHT) is as an autosomal dominant trait characterized by frequent nose bleeds, mucocutaneous telangiectases, arteriovenous malformations (AVMs) of the lung, liver and brain, and gastrointestinal bleedings due to telangiectases. HHT is originated by mutations in genes whose encoded proteins are involved in the transforming growth factor β (TGF-β) family signalling of vascular endothelial cells. In spite of the great advances in the diagnosis as well as in the molecular, cellular and animal models of HHT, the current treatments remain just at the palliative level...
October 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28758529/targeting-endothelin-1-receptor-%C3%AE-arrestin1-network-for-the-treatment-of-ovarian-cancer
#17
REVIEW
Laura Rosanò, Roberta Cianfrocca, Rosanna Sestito, Piera Tocci, Valeriana Di Castro, Anna Bagnato
Endothelin-1 receptor (ET-1R)/β-arrestin1 (β-arr1) signaling is dysregulated in ovarian cancer. This signaling circuit enables cancer cells to engage several signaling and transcriptional networks that are pervasively intertwined, and represent a potential therapeutic target for developing novel agents for ovarian cancer treatment. Areas covered: In this article, we discuss the role of the signaling network between ET-1R and key pathways mediated by the scaffold protein β-arr1, as part of signaling complex, or as a transcription co-activator, promoting precise control of transcription of different genes, including ET-1...
October 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28820612/the-potential-of-signal-peptide-peptidase-as-a-therapeutic-target-for-hepatitis-c
#18
REVIEW
Kohji Moriishi
Chronic infection with hepatitis C virus (HCV) causes liver steatosis, cirrhosis, metabolic syndrome with inflammation, and eventually leads to hepatocellular carcinoma. HCV core protein is a well-known capsid protein and pathogenic factor related to lipid accumulation, type 2 diabetes mellitus, and carcinogenesis. Cleavage of the C-terminal transmembrane region by signal peptide peptidase (SPP) is required for maturation of the core protein. Areas covered: Herein, this review details the general aspects of the structure, lifecycle, pathogenesis, and maturation of the HCV core protein, the function of SPP, and clinically available direct-acting antivirals (DAAs)...
September 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28816549/implications-of-bcl-2-and-its-interplay-with-other-molecules-and-signaling-pathways-in-prostate-cancer-progression
#19
REVIEW
Ju-Ha Kim, Hyemin Lee, Eun Ah Shin, Dong Hee Kim, Jhin Baek Choi, Sung-Hoon Kim
Among several genetic alterations involved in the progression of prostate cancer, B cell lymphoma gene number 2 (BCL-2) is an important target molecule in the progression of androgen-independent prostate cancer (AIPC) after androgen ablation or castration. Nevertheless, the molecular mechanism of BCL-2 in prostate cancer progression remains elusive and controversial. In the current review, we discuss the critical role of BCL-2 in the carcinogenesis of prostate cancer with experimental evidences on the BCL-2 molecular networks in AIPC and androgen-dependent prostate cancer (ADPC) and subsequently suggest perspective research targeting BCL-2...
September 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28786708/annexin-a1-and-specialized-proresolving-lipid-mediators-promoting-resolution-as-a-therapeutic-strategy-in-human-inflammatory-diseases
#20
REVIEW
Luiza Oliveira Perucci, Michelle Amantéa Sugimoto, Karina Braga Gomes, Luci Maria Dusse, Mauro Martins Teixeira, Lirlândia Pires Sousa
The timely resolution of inflammation is essential to restore tissue homeostasis and to avoid chronic inflammatory diseases. Resolution of inflammation is an active process modulated by various proresolving mediators, including annexin A1 (AnxA1) and specialized proresolving lipid mediators (SPMs), which counteract excessive inflammatory responses and stimulate proresolving mechanisms. Areas covered: The protective effects of AnxA1 and SPMs have been extensively explored in pre-clinical animal models. However, studies investigating the function of these molecules in human diseases are just emerging...
September 2017: Expert Opinion on Therapeutic Targets
journal
journal
39856
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"